Gastric endoscopic submucosal dissection in Western countries: current and future perspective

Endoscopy 2024; 56(05): 391-392
DOI: 10.1055/a-2219-3129

Letter to the editor

Yasutoshi Shiratori

¹Division of Gastroenterology, Maimonides Medical Center, Brooklyn, United States

,

Anthony Kalloo

²The Johns Hopkins University School of Medicine, Baltimore, United States (Ringgold ID: RIN1500)

References
1 Bhandari P, Abdelrahim M, Alkandari AA. et al. Predictors of long-term outcomes of endoscopic submucosal dissection of early gastric neoplasia in the West: a multicenter study. Endoscopy 2023; 55: 898-906
2 Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer 2023; 26: 1-25
3 Takizawa K, Ono H, Hasuike N. et al. A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010). Gastric Cancer 2021; 24: 479-491
4 Shiratori Y, Niikura R, Ishii N. et al. Vonoprazan versus proton pump inhibitors for postendoscopic submucosal dissection bleeding in the stomach: a multicenter population-based comparative study. Gastrointest Endosc 2022; 95: 72-79.e73
5 Ngamruengphong S, Ferri L, Aihara H. et al. Efficacy of endoscopic submucosal dissection for superficial gastric neoplasia in a large cohort in North America. Clin Gastroenterol Hepatol 2021; 19: 1611-1619.e1611